Medline exits Medline Brand beds, estimates up to $220 million in costs

Medline Inc. (MDLN) said in a regulatory filing Wednesday that it has initiated a voluntary field action covering the removal, discontinuation and market exit of all Medline Brand beds.

The action began on Oct. 14, 2026. It covers homecare beds, bariatric beds and long-term care beds, along with associated pendants, accessories, replacement parts and bed-containing order packages.

The affected products sit within the company's Front Line Care product category in its Medline Brand segment.

Net sales of the affected products were approximately $60 million for the twelve months ended June 27, 2026.

The company estimates total costs of up to $220 million. Those costs include product discontinuation, inventory impairment and disposal costs, and customer credits.

The company said it is too early to ascertain the total costs of the action.

The costs are expected to be incurred in 2026 and 2027. They will be excluded from Adjusted EBITDA, a measure of earnings before interest, taxes, depreciation and amortization.

The estimated range reflects uncertainty about future customer participation. Actual customer credits may differ materially from the estimate.

The company does not expect the action to have a material impact on its financial results for fiscal year 2026, including the full year 2026 guidance it provided on Aug. 5, 2026.

The filing says additional information is available on the company's corporate website, under the Press Releases & Media Statements section of the News and Insights page.